ERα17p, an ERα P 295-T 311 fragment, modifies the migration of breast cancer cells, through actin cytoskeleton rearrangements

Journal of Cellular Biochemistry

Volumn 112, Issue 12, 2011, Pages 3786-3796

  Kampa, Marilena ^a,b   Pelekanou, Vassiliki ^a,b   Gallo, Dominique ^b,c   Notas, George ^a   Troullinaki, Maria ^a   Pediaditakis, Iosif ^a   Charalampopoulos, Ioannis ^a   Jacquot, Yves ^c,d   Leclercq, Guy ^b,c   Castanas, Elias ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b JULES BORDET INSTITUTE   (Belgium)

^c Fondation Pierre Gilles de Gennes Pour la Recherche   (France)

^d Centre National de la Recherche Scientifique   (France)

Author keywords

Actin cytoskeleton; Breast cancer; Estrogen receptor (membrane); Migration

Indexed keywords

ACTIN CYTOSKELETON; ANDROGEN; CYTOSKELETON PROTEIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA 17P; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHO FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BREAST CANCER; CELL MIGRATION; CELL MOTILITY; CELLULAR DISTRIBUTION; HUMAN; IMMUNOBLOTTING; PRIORITY JOURNAL; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACTINS; BIOPOLYMERS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOSKELETON; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; NEOPLASM METASTASIS; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 80055015773     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23309     Document Type: Article

References (41)

1. Acconcia F, Ascenzi P, Bocedi A, Spisni E, Tomasi V, Trentalance A, Visca P, Marino M,. 2005. Palmitoylation-dependent estrogen receptor alpha membrane localization: Regulation by 17beta-estradiol. Mol Biol Cell 16: 231-237. (Pubitemid 40028339)
2. Acconcia F, Barnes CJ, Kumar R,. 2006. Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology 147: 1203-1212. (Pubitemid 43244353)
3. Brooks SA, Lomax-Browne HJ, Carter TM, Kinch CE, Hall DM,. 2010. Molecular interactions in cancer cell metastasis. Acta Histochem 112: 3-25.
4. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, Bologa CG, Leitao A, Brailoiu E, Deliu E, Dun NJ, Sklar LA, Hathaway HJ, Arterburn JB, Oprea TI, Prossnitz ER,. 2009. In vivo effects of a GPR30 antagonist. Nat Chem Biol 5: 421-427.
5. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI,. 2002. Estrogen action via the G protein-coupled receptor, GP R30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16: 70-84. (Pubitemid 34044499)
6. Gallo D, Haddad I, Duvillier H, Jacquemotte F, Laios I, Laurent G, Jacquot Y, Vinh J, Leclercq G,. 2008a. Trophic effect in MCF-7cells of ERalpha17p, a peptide corresponding to a platform regulatory motif of the estrogen receptor alpha-underlying mechanisms. J Steroid Biochem Mol Biol 109: 138-149.
7. Gallo D, Haddad I, Laurent G, Vinh J, Jacquemotte F, Jacquot Y, Leclercq G,. 2008b. Regulatory function of the P295-T311 motif of the estrogen receptor alpha-does proteasomal degradation of the receptor induce emergence of peptides implicated in estrogenic responses? Nucl Recept Signal 6: e007.
8. Gallo D, Jacquemotte F, Cleeren A, Laios I, Hadiy S, Rowlands MG, Caille O, Nonclercq D, Laurent G, Jacquot Y, Leclercq G,. 2007a. Calmodulin- independent, agonistic properties of a peptide containing the calmodulin binding site of estrogen receptor alpha. Mol Cell Endocrinol 268: 37-49. (Pubitemid 46437352)
9. Gallo D, Jacquot Y, Cleeren A, Jacquemotte F, Laãos I, Laurent G, Leclercq G,. 2007b. Molecular basis of agonistic activity of ER 17p, a synthetic peptide corresponding to a sequence located at the N-terminal part of the estrogen receptor ligand binding domain. Lett Drug Des Discov 4: 346-355. (Pubitemid 47025415)
10. Gallo D, Jacquot Y, Laurent G, Leclercq G,. 2008c. Calmodulin, a regulatory partner of the estrogen receptor alpha in breast cancer cells. Mol Cell Endocrinol 291: 20-26.
11. Giretti MS, Fu XD, De Rosa G, Sarotto I, Baldacci C, Garibaldi S, Mannella P, Biglia N, Sismondi P, Genazzani AR, Simoncini T,. 2008. Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS One 3: e2238.
12. Heasman SJ, Ridley AJ,. 2008. Mammalian Rho GTPases: New insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 9: 690-701.
13. Hua K, Feng W, Cao Q, Zhou X, Lu X, Feng Y,. 2008. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. Int J Oncol 33: 959-967.
14. Insall RH, Machesky LM,. 2009. Actin dynamics at the leading edge: From simple machinery to complex networks. Dev Cell 17: 310-322.
15. Jordan C,. 2002. Historical perspective on hormonal therapy of advanced breast cancer. Clin Ther 24 (Suppl A): A3-A16. (Pubitemid 34206383)
16. Kampa M, Castanas E,. 2006. Membrane steroid receptor signaling in normal and neoplastic cells. Mol Cell Endocrinol 246: 76-82. (Pubitemid 43239607)
17. Kampa M, Kogia C, Theodoropoulos PA, Anezinis P, Charalampopoulos I, Papakonstanti EA, Stathopoulos EN, Hatzoglou A, Stournaras C, Gravanis A, Castanas E,. 2006. Activation of membrane androgen receptors potentiates the antiproliferative effects of paclitaxel on human prostate cancer cells. Mol Cancer Ther 5: 1342-1351. (Pubitemid 43881328)
18. Kampa M, Nifli AP, Charalampopoulos I, Alexaki VI, Theodoropoulos PA, Stathopoulos EN, Gravanis A, Castanas E,. 2005. Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis. Exp Cell Res 307: 41-51. (Pubitemid 40732732)
19. Kampa M, Pelekanou V, Castanas E,. 2008. Membrane-initiated steroid action in breast and prostate cancer. Steroids 73: 953-960.
20. Leclercq G, Lacroix M, Laios I, Laurent G,. 2006. Estrogen receptor alpha: Impact of ligands on intracellular shuttling and turnover rate in breast cancer cells. Curr Cancer Drug Targets 6: 39-64.
21. Levin ER,. 2009. Plasma membrane estrogen receptors. Trends Endocrinol Metab 20: 477-482.
22. Lin BC, Suzawa M, Blind RD, Tobias SC, Bulun SE, Scanlan TS, Ingraham HA,. 2009. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res 69: 5415-5423.
23. Madeo A, Maggiolini M,. 2010. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res 70: 6036-6046.
24. Malek D, Gust R, Kleuser B,. 2006. 17-Beta-estradiol inhibits transforming-growth-factor-beta-induced MCF-7 cell migration by Smad3-repression. Eur J Pharmacol 534: 39-47. (Pubitemid 43384181)
25. Matsuoka H, Tsubaki M, Yamazoe Y, Ogaki M, Satou T, Itoh T, Kusunoki T, Nishida S,. 2009. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. Exp Cell Res 315: 2022-2032.
26. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D,. 2009. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 28: 523-532.
27. Papakonstanti EA, Kampa M, Castanas E, Stournaras C,. 2003. A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors. Mol Endocrinol 17: 870-881. (Pubitemid 36539577)
28. Pelekanou V, Kampa M, Gallo D, Notas G, Troullinaki M, Duvillier H, Jacquot Y, Stathopoulos EN, Castanas E, Leclercq G,. 2011. The estrogen receptor alpha-derived peptide ERalpha17p (P(295)-T(311)) exerts pro-apoptotic actions in breast cancer cells in vitro and in vivo, independently from their ERalpha status. Mol Oncol 5: 36-47.
29. Peng J, Sengupta S, Jordan VC,. 2009. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med Chem 9: 481-499.
30. Platet N, Cunat S, Chalbos D, Rochefort H, Garcia M,. 2000. Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. Mol Endocrinol 14: 999-1009. (Pubitemid 32250517)
31. Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, Geliebter J, Tiwari RK,. 2010. Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid 20: 33-41.
32. Rochefort H, Platet N, Hayashido Y, Derocq D, Lucas A, Cunat S, Garcia M,. 1998. Estrogen receptor mediated inhibition of cancer cell invasion and motility: An overview. J Steroid Biochem Mol Biol 65: 163-168. (Pubitemid 28335602)
33. Sanchez AM, Flamini MI, Fu XD, Mannella P, Giretti MS, Goglia L, Genazzani AR, Simoncini T,. 2009. Rapid signaling of estrogen to WAVE1 and moesin controls neuronal spine formation via the actin cytoskeleton. Mol Endocrinol 23: 1193-1202.
34. Sanchez AM, Simoncini T,. 2010. Extra-nuclear signaling of ERalpha to the actin cytoskeleton in the central nervous system. Steroids 75: 528-532.
35. Schmitz AA, Govek EE, Bottner B, Van Aelst L,. 2000. Rho GTPases: Signaling, migration, and invasion. Exp Cell Res 261: 1-12.
36. Sengupta S, Jordan VC,. 2008. Selective estrogen modulators as an anticancer tool: Mechanisms of efficiency and resistance. Adv Exp Med Biol 630: 206-219.
37. Szego CM, Davis JS,. 1967. Adenosine 3',5'-monophosphate in rat uterus: Acute elevation by estrogen. Proc Natl Acad Sci USA 58: 1711-1718.
38. Thomas P, Pang Y, Filardo EJ, Dong J,. 2005. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146: 624-632. (Pubitemid 40129818)
39. Tiraby C, Hazen BC, Gantner ML, Kralli A,. 2011. Estrogen-related receptor gamma promotes mesenchymal-to-epithelial transition and suppresses breast tumor growth. Cancer Res 71: 2518-2528.
40. Wendler A, Baldi E, Harvey BJ, Nadal A, Norman A, Wehling M,. 2010. Position paper: Rapid responses to steroids: Current status and future prospects. Eur J Endocrinol 162: 825-830.
41. Yu J, Bian D, Mahanivong C, Cheng RK, Zhou W, Huang S,. 2004. p38 Mitogen-activated protein kinase regulation of endothelial cell migration depends on urokinase plasminogen activator expression. J Biol Chem 279: 50446-50454. (Pubitemid 39577863)